Predictive and concurrent validity of cartilage thickness change as a marker of knee osteoarthritis progression: data from the Osteoarthritis Initiative

摘要

Summary Objective To investigate the predictive and concurrent validity of magnetic resonance imaging (MRI)-based cartilage thickness change between baseline (BL) and year-two (Y2) follow-up (predictive validity) and between Y2 and Y4 follow-up (concurrent validity) for symptomatic and radiographic knee osteoarthritis (OA) progression during Y2→Y4. Methods 777 knees from 777 Osteoarthritis Initiative (OAI) participants (age: 61.3?±?9.0 years, BMI: 30.1?±?4.8?kg/m 2 ) with Kellgren Lawrence (KL) grade 1–3?at Y2 (visit before progression interval) had cartilage thickness measurements from 3T MRI at BL, Y2 ( n ?=?777), and Y4 ( n ?=?708). Analysis of covariance and logistic regression were used to assess the association of pain progression (≥9 WOMAC units [scale 0–100], n ?=?205/572 with/without progression) and radiographic progression (≥0.7?mm minimum joint space width (mJSW) loss, n ?=?166/611 with/without progression) between Y2 and Y4 with preceding (BL→Y2) and concurrent (Y2→Y4) change in central medial femorotibial (cMFTC) compartment cartilage thickness. Results Symptomatic progression was associated with concurrent (Y2→Y4:??305?±?470?μm vs??155?±?346?μm, Odds ratios (OR)?=?1.5 [1.2, 1.7]) but not with preceding cartilage thickness loss in cMFTC (?150?±?276?μm vs??151?±?299?μm, OR?=?0.9 95% CI: [0.8, 1.1]). Radiographic progression, in contrast, was significantly associated with both concurrent (?542?±?550?μm vs??98?±?255?μm, OR?=?3.4 [2.6, 4.3]) and preceding cMFTC thickness loss (?229?±?355?μm vs??130?±?270?μm, OR?=?1.3 [1.1, 1.5]). Conclusions These results extend previous reports that did not discern predictive vs concurrent associations of cartilage thickness loss with OA progression. The observed predictive and concurrent validity of cartilage thickness loss for radiographic progression and observed concurrent validity for symptomatic progression provide an important step in qualifying cartilage thickness loss as a biomarker of knee OA progression. Clinicaltrials.gov identification NCT00080171 .